Comparison between body composition parameters and response to neoadjuvant chemotherapy by using pre-treatment PET CT in locally advanced breast cancer

Yırgın, İnci Kızıldağ; Has, Duygu; Arslan, Gözde; Aydın, Esra; Sarı, Murat; Önder, Semen; Şanlı, Yasemin; Cabıoğlu, Neslihan; Karanlık, Hasan; Tükenmez, Mustafa; Dursun, Memduh; Müslümanoğlu, Mahmut; Özmen, Vahit

doi:10.1016/j.ejro.2020.100286

Cited by 4 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analysis of BoCo seems a more effective predictor of pharmacokinetics but unlike BMI, body composition requires instrumental measurements [27][28]. The majority of studies in cancer patients have used either CT-de ned skeletal muscle at the third lumbar vertebra (L3) level or dual-energy X-ray absorptiometry (DXA) CT-based analysis or DXA scan, while the use of BIA has been very limited, even though this tool is easy to use, less expensive and without any radiation-associated risk [29][30][31][32][33].…”

Section: Discussionmentioning

confidence: 99%

The role of body composition in neurological and hematologic toxicity in breast cancer patients undergoing neoadjuvant chemotherapy. The COMBOTOX study

Leone,

Filippone,

Maggiore

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose: Neoadjuvant chemotherapy (NAC) has a well estabilished role in locally advanced or chemoresponsive breast cancers (BC). Chemotherapic regimens are effective when patients receive the optimal doses. Toxicities are common in overweight/obese patients but may occur also in normal weight counterparts. This lead to delays, reductions or discontinuation of treatment, with impact on outcomes. Current dosing is based on body weight and predicted Body Surface Area (BSA). These parameters do not take into consideration the individual variations of fat mass (FM) and fat-free mass (FFM) that affect pharmacokinetics. Assessment of body composition (BoCo), rather than Body Mass Index (BMI), could help to better plan chemotherapy and reduce drug-related toxicities. Our aim was to analyze the correlations between body weight, anthropometric measures, BoCO and toxicities related to NAC in non metastatic BC patients. Methods: This is a retrospective observational cohort study that includes 120 consecutive BC patients undergoing NAC, enrolled between May 2018 and December 2020. All patients received an evaluation of anthropometric parameters (height, weight, waist and hip circumference, BMI) and an assessment of BoCo using Segmental Multi Frequency-Bioelectrical Impedance Analysis. Results: A logistic regression models confirmed that a higher FM was associated with a higher rate of neurological and hematological toxicities in protocols containing Platinum. Moreover, patients with a low FFM% have a higher risk for hematologic toxicity in protocols containing Platinum. Conclusion: A routinary assessment of BoCo, in addition to evaluation of anthropometric measures and BMI, could allow to personalize chemotherapy doses, in order to reduce chemotherapy-related toxicities.

show abstract

Section: Discussionmentioning

confidence: 99%

The role of body composition in neurological and hematologic toxicity in breast cancer patients undergoing neoadjuvant chemotherapy. The COMBOTOX study

Leone,

Filippone,

Maggiore

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

The role of body composition in neurological and hematologic toxicity in a retrospective analysis of 120 breast cancer patients undergoing neoadjuvant chemotherapy: the COMBOTOX study

Di Leone,

Filippone,

Maggiore

et al. 2024

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose Neoadjuvant chemotherapy (NAC) has a well-established role in locally advanced or chemoresponsive breast cancers (BC). Chemotherapic regimens are effective when patients receive the optimal doses. Toxicities are common in overweight/obese patients but may occur also in normal weight counterparts. This leads to delays, reductions, or discontinuation of treatment, with impact on outcomes. Current dosing is based on body weight and predicted Body Surface Area (BSA). These parameters do not take into consideration the individual variations of fat mass (FM) and fat-free mass (FFM) that affect pharmacokinetics. Assessment of body composition (BoCo), rather than Body Mass Index (BMI), could help to better plan chemotherapy and reduce drug-related toxicities. Our aim was to analyze the correlations between body weight, anthropometric measures, BoCO, and toxicities related to NAC in non-metastatic BC patients. Methods This is a retrospective observational cohort study that includes 120 consecutive BC patients undergoing NAC, enrolled between May 2018 and December 2020. All patients received an evaluation of anthropometric parameters (height, weight, waist and hip circumference, BMI) and an assessment of BoCo using Segmental Multi-Frequency-Bioelectrical Impedance Analysis. Results A logistic regression models confirmed that a higher FM was associated with a higher rate of neurological and hematologic toxicities in protocols containing Platinum. Moreover, patients with a low FFM% have a higher risk for hematologic toxicity in protocols containing Platinum. Conclusion A routine assessment of BoCo, in addition to evaluation of anthropometric measures and BMI, could allow to personalize chemotherapy doses, in order to reduce chemotherapy-related toxicities.

show abstract

Deep learning radiomics under multimodality explore association between muscle/fat and metastasis and survival in breast cancer patients

Miao

Jia

Cheng

et al. 2022

Briefings in Bioinformatics

View full text Add to dashboard Cite

Sarcopenia is correlated with poor clinical outcomes in breast cancer (BC) patients. However, there is no precise quantitative study on the correlation between body composition changes and BC metastasis and survival. The present study proposed a deep learning radiomics (DLR) approach to investigate the effects of muscle and fat on distant metastasis and death outcomes in BC patients. Image feature extraction was performed on 4th thoracic vertebra (T4) and 11th thoracic vertebra (T11) on computed tomography (CT) image levels by DLR, and image features were combined with clinical information to predict distant metastasis in BC patients. Clinical information combined with DLR significantly predicted distant metastasis in BC patients. In the test cohort, the area under the curve of model performance on clinical information combined with DLR was 0.960 (95% CI: 0.942–0.979, P < 0.001). The patients with distant metastases had a lower pectoral muscle index in T4 (PMI/T4) than in patients without metastases. PMI/T4 and visceral fat tissue area in T11 (VFA/T11) were independent prognostic factors for the overall survival in BC patients. The pectoralis muscle area in T4 (PMA/T4) and PMI/T4 is an independent prognostic factor for distant metastasis-free survival in BC patients. The current study further confirmed that muscle/fat of T4 and T11 levels have a significant effect on the distant metastasis of BC. Appending the network features of T4 and T11 to the model significantly enhances the prediction performance of distant metastasis of BC, providing a valuable biomarker for the early treatment of BC patients.

show abstract

Comparison between body composition parameters and response to neoadjuvant chemotherapy by using pre-treatment PET CT in locally advanced breast cancer

Cited by 4 publications

References 30 publications

The role of body composition in neurological and hematologic toxicity in breast cancer patients undergoing neoadjuvant chemotherapy. The COMBOTOX study

The role of body composition in neurological and hematologic toxicity in breast cancer patients undergoing neoadjuvant chemotherapy. The COMBOTOX study

The role of body composition in neurological and hematologic toxicity in a retrospective analysis of 120 breast cancer patients undergoing neoadjuvant chemotherapy: the COMBOTOX study

Deep learning radiomics under multimodality explore association between muscle/fat and metastasis and survival in breast cancer patients

Contact Info

Product

Resources

About